Navigation Links
NEBA Health earns patent for integration of NEBA biomarker with clinician's ADHD evaluation
Date:8/15/2013

BOULDER, Colo., Aug. 15, 2013 /PRNewswire/ -- NEBA Health, LLC announces today that Dr. Steven M. Snyder, Research and Development Vice President, has earned US Patent 8,509,884.  The patent protects a key aspect of the NEBA system:  integrating the biomarker with a clinician's workup for ADHD.  "NEBA is not a standalone diagnostic," said Dr. Snyder.  "After the clinician's ADHD evaluation, NEBA helps them determine if the symptoms are due to ADHD or if further testing is warranted."  

"Integrating the NEBA biomarker with a clinician's initial diagnostic impression can bring a clinician's diagnosis more in line with that of multidisciplinary team," said Dr. Snyder.  Research supports that compared to a clinician alone, a multidisciplinary team is better able to determine if ADHD-like symptoms are accounted for by another condition. 

In order to diagnose ADHD, a clinician not only observes criteria regarding behavioral symptoms and impairment, but also must determine whether symptoms would be better accounted for by another condition.  Because ADHD shares symptoms with other disorders, the diagnosis may be difficult.  According to the US Center for Disease Control and Prevention (CDC), 9.5% of all children and adolescents have an ADHD diagnosis.  The ADHD diagnosis rate is increasing.  CDC states that rates of ADHD diagnosis increased an average of 3% per year from 1997 to 2006 and an average of 5.5% per year from 2003 to 2007.

"In their ADHD evaluation, clinicians may be challenged in the current medical environment to determine the primary diagnosis when overlapping symptoms are present," said Howard Merry, President of NEBA Health.  "We are delighted that the USPTO has awarded Dr. Snyder the patent.  It covers NEBA's core technology, and it's another validation point for the 7 years we spent developing and validating NEBA." 

About NEBA Health

NEBA Health has developed the first FDA approved medical device based on brain waves to help assess ADHD.  The device, NEBA, is cleared in the USA (K112711), CE marked, and Health Canada licensed.  To our knowledge, the NEBA FDA validation study is the largest ADHD diagnostic study of this nature ever conducted (275 subjects at 13 clinical sites).  We have ongoing work in ADHD, depression, and dementia.  Our technologies are NIEAAs (Neuropsychiatric Interpretive EEG-based Assessment Aids).  NEBA Health is privately held.


'/>"/>
SOURCE NEBA Health, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First students at new College of Pharmacy to begin classes next week at UNT Health Science Center
2. mHealth Identified as Critical Strategy in Medication Adherence Programs
3. iSALUS Healthcare Expands Revenue Cycle Management Services with Billnet Solutions
4. Natus Neurology Incorporated Receives 510(k) & Health Canada Clearance And Launches New Electrodiagnostic System In U.S. & Canada
5. Millennium HealthCare Inc. Featured in Forbes
6. Wolters Kluwer Health Launches Nursing Drug Handbook Specialty Apps
7. PinnacleHealth, Meridian Health Select Perioperative IT from Surgical Information Systems
8. Hospira to Present at the Morgan Stanley Global Healthcare Conference
9. Chinas Strong Economic Growth and Healthcare Investments Generate Success for CPhI
10. Endo and Metamark Announce Sale of HealthTronics Laboratory Solutions
11. Real Time Location Systems (RTLS) Market in Healthcare Industry 2011 - 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2020)... México (PRWEB) , ... July 03, 2020 , ... ... of the Riviera Maya began to welcome visitors at approved capacities, reactivating the ... cleaning and sanitizing, among other preventive actions. , The most recent opening was ...
(Date:7/4/2020)... (PRWEB) , ... July 03, 2020 , ... By Heidi ... and we’ve retreated into our homes for cover, Assuaged, Inc. is going ... from all over the globe this year to get their feet wet in marketing, ...
(Date:7/2/2020)... ... July 02, 2020 , ... AllenComm, the leader in transformative ... Omni Awards for visually compelling compliance training , onboarding , brand ... exceed client and industry expectations as a digital transformation partner for learning and development ...
Breaking Medicine Technology:
(Date:7/4/2020)... FRANCISCO, Calif. (PRWEB) , ... July 03, 2020 ... ... scientific breakthroughs are prominently featured in Biocompare’s latest content hub— Future Lab: COVID-19 ... to showcase the latest advancements, trends, news, and products within specific scientific niches. ...
(Date:7/4/2020)... ... July 03, 2020 , ... Houston Life coach, Rashad Garrett, has thrown ... with the launch of his new app, Faith Of A Mustard Seed (FOAMS). , ... with mental health issues. In fact, a Federal Agency emergency helpline dedicated to helping ...
(Date:7/4/2020)... ... July 03, 2020 , ... MemoryCare.com ... has announced the Best Memory Care Facilities in Charleston, South Carolina. The guide ... and amenities. , According to the Alzheimer’s Association , 5.6 million ...
(Date:7/2/2020)... ... July 02, 2020 , ... Temprian, a ... autoimmune diseases. Its lead indication is vitiligo. Vitiligo patients develop progressive depigmentation ... , While vitiligo is equally prevalent in all ethnic groups, it is ...
(Date:7/2/2020)... ... 02, 2020 , ... Dr. Christine Blaine has earned a stellar ... offices located in Staten Island, Huntington and NYC, NY. Her former Manhattan clinic, ... suite at The Parlor NYC at 160 Madison Avenue. Blaine Plastic Surgery ...
Breaking Medicine News(10 mins):